Kite Pharma Inc


Canaccord Weighs In On Kite Pharma Inc (KITE) Following KTE-C19 Death Update

Canaccord analyst John Newman weighed in today with a few insights on Kite Pharma Inc (NASDAQ:KITE), after the company informed investors that there was one …

Monday Morning Insights: Tesla Motors Inc, Nokia Corporation (ADR), AVEO Pharmaceuticals, Inc., Kite Pharma Inc

Tesla Motors Inc (NASDAQ:TSLA) shares are up 4.96% in pre-market trading to $255.

Company Update (NASDAQ:KITE): Kite Pharma Inc Provides Update on KTE-C19 Clinical Trial

Kite Pharma Inc (NASDAQ:KITE) provided an update from the Company’s ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin’s lymphoma …

Canaccord Pounds the Table on Kite Pharma Inc (KITE)

Canaccord analyst John Newman was out pounding the table on Kite Pharma Inc (NASDAQ:KITE), reiterating a Buy rating and price target of $90, …

Company Update (NASDAQ:KITE): Kite Pharma Inc Reports 2Q:15 Financial Results

Kite Pharma Inc (NASDAQ:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today …

Stock Update (NASDAQ:KITE): Kite Pharma Inc and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19

Kite Pharma Inc (NASDAQ:KITE) and The Leukemia & Lymphoma Society (LLS) announced that they have entered into a partnership to enhance the development of …

Stock Update (NASDAQ:KITE): Kite Pharma Inc and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19

Kite Pharma Inc (NASDAQ:KITE) and The Leukemia & Lymphoma Society (LLS) announced that they have entered into a partnership to enhance the development of …

Tuesday Morning Pre-Market Insights: Global X Funds (GREK), Juno Therapeutics Inc (JUNO), Stratasys, Ltd. (SSYS), Kite Pharma Inc (KITE)

Global X Funds (NYSEARCA:GREK) shares are up 3.4% in pre-market trading to $9.

Mizuho Reiterates Optimistic View on Kite Pharma Inc Following Investor Day

Mizuho analyst Peter Lawson weighed in with some commentary on Kite Pharma Inc (NASDAQ:KITE) following the company’s Investor Day. The analyst reiterated an Outperform …

Stock Update (NASDAQ:KITE): Kite Pharma Inc and bluebird bio Inc Announce Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers

Kite Pharma Inc (NASDAQ:KITE) and bluebird bio, Inc. announced that they have entered into a collaboration agreement to co-develop and co-commercialize second generation T …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts